Karuna Therapeutics, Inc. KRTX made its public debut Friday morning, opening at $18.50 after being priced at $16 per share.
Karuna focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet need.
The company's lead product candidate KarXT is in a midstage trial for the treatment of acute psychosis in patients with schizophrenia. It expects to release top-line data from the trial in late 2019.
Karuna is also planning to initiate clinical trials of KarXT to evaluate its therapeutic benefit in other central nervous system disorders, including psychosis in Alzheimer's disease as well as pain.
Goldman Sachs, Citigroup, Wells Fargo Securities and Wedbush are the underwriters for the offering.
The stock traded around $18.07 per share at time of publication.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
